Cure My Disease

Don't miss your cure!

 Log in / Sign up

Would families trade daily growth hormone shots for weekly ones?

NCT ID NCT06542809

NEW Knowledge-focused Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Children with growth hormone deficiency often need daily injections, which can be hard to keep up with. Researchers in Belgium and Luxembourg are asking families in the BELGROW registry to fill out a questionnaire about whether they would consider switching to long-acting growth hormone, which is given weekly, every two weeks, or monthly. The survey asks what benefits families expect, what side effects worry them, and what information they want from their doctor. Answers will be compared across age groups, treatment reasons, and how long each child has been on daily shots.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the survey shows families want weekly shots, it could guide doctors toward offering long-acting growth hormone to the children most likely to benefit.
What could go wrong
This is a questionnaire, not a treatment trial, so it cannot prove that long-acting growth hormone works better or is safer. Families' stated preferences may not match what they actually choose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

500 people

The number who actually took part.

Started

Apr 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 day to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Belgian and Luxembourgish patients currently under rhGh treatment in its various official indications (as per the Belgian RIZIV/INAMI monitor : growth hormone deficiency, Turner Syndrome, chronic renal insufficiency, Prader-Willi syndrome, Small for gestational age, Noonan Syndrome, SHOX gene deficiency) and included in the BELGROW Registry * Male -female * 0-18 years * Free written or e-consent and oral consent Exclusion Criteria: * No exclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic renal insufficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease Noonan syndrome pituitary dwarfism Prader-Willi syndrome SHOX-related short stature Turner syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Growth hormone deficiency

Contacts and locations

Locations

  • Cliniques Universitaires Saint-Luc

    Brussels, Woluwe-saint-lambert, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.